Prostate Cancer Clinical Trials in Detroit

Showing 161-180 of 206 trials

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

NCT02514213

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Prostate Cancer

Inovio Pharmaceuticals62 participantsStarted Jul 2015

Baltimore, Maryland, United States • Detroit, Michigan, United States • Omaha, Nebraska, United States +7 more locations

COMPLETEDPHASE3< 1 mile

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases. PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have bone metastases from breast or prostate cancer.

Breast CancerMetastatic CancerPain+1 more

Radiation Therapy Oncology Group949 participantsStarted Feb 1998

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +250 more locations

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Prostate Cancer Trials in Other Cities

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Carbon-11 Labeled Sarcosine in Prostate Cancer

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Other Conditions in Detroit